Furthermore, CD74-ROS1 is the most common form of ROS1 fusion in NSCLC, and CD74-NRG1 gene fusion activates genomic alterations in aggressive mucinous adenocarcinomas, offering potential therapeutic opportunities for lung tumor subtypes that have not yet been effectively treated (17). Here, ROS1 is linked to mucinous adenocarcinoma.